Hualan Co., Ltd. released its 2026 interim report, showing total operating revenue of 298 million yuan, down 3.47% from the same period last year. Net profit attributable to the parent company was 7.6726 million yuan, down 82.46% year-on-year. Net cash inflow from operating activities was 22.352 million yuan, down 53.97% year-on-year. The company's latest asset-liability ratio was 15.30%, gross margin was 39.02%, return on equity was 0.35%, and diluted earnings per share was 0.04 yuan. The number of shareholders was 11,800, and the top ten shareholders held 53.84% of the total share capital.
Jiangsu Hualan New Pharmaceutical Material Co. Ltd.Net profit down 82.46% year-on-year in H1 2026.
